

Brisbane Today  15° / 27° >**The Courier Mail**
We're for youHi, George  ▾My
News
Today's
Paper

QLD

World

Sport

Business

Opinion

Education

Health

Lifestyle

Entertainment

Puzzles^{NEW}**Business** [Stockhead](#)

ASX healthcare stocks riding the point-



Lumos and Atomo are making waves in point-of-care testing. Pic: Getty Images

Point-of-care testing emerges as one of the most disruptive shifts in global diagnostics

More local stories

Diagnostic test out of laboratories and into GP clinics, pharmacies and homes leading to faster results and treatment

Developed in the late 1970s home pregnancy tests were among the first widely adopted POC diagnostics, allowing women to receive accurate results within minutes with ovulation tests following.

Feb 1, 2023 6:11 PM AEST

Feb 1, 2023 6:11 PM AEST

Feb 1, 2023 6:11 PM AEST

Lumos Diagnostics' (ASX:LDX) flagship rapid point-of-care finger blood test FebriDx is designed to differentiate between viral and bacterial respiratory infections.

The test aims to help reduce the inappropriate and unnecessary use of antibiotics, recognised as a key driver of the growing global public health challenge of antimicrobial resistance (AMR).

My News Feed [Read More >](#)

Lumos chief executive Doug Ward told *Stockhead* the test gave clinicians the confidence to prescribe antibiotics more appropriately, rather than relying on overlapping symptoms. The test received US FDA 510(k) clearance in 2023, but Ward said the biggest commercial milestone came earlier this year when it secured a [Clinical Laboratory Improvement Amendments \(CLIA\) waiver](#).

Leaders & Companies **SA News** **Business**
"That means clinicians can make an informed antibiotic decision in the exam room rather than relying on overlapping symptoms." **Blood spilt as chair directors ousted at** **Mayfair Hotel to be transformed after** **Digital air traffic control towers not fit for WFH, says Airservices boss**
The test received US FDA 510(k) clearance in 2023, but Ward said the biggest commercial milestone came earlier this year when it secured a [Clinical Laboratory Improvement Amendments \(CLIA\) waiver](#).

This allows FebriDx to be used in more than 300,000 waived testing sites across the US, including physician offices, urgent care centres and retail clinics.

Good Afternoon George Recommended based on what you've read

Feb 1, 2023 6:11 PM AEST

Horse Racing **Sunshine Coast** **NRL**
"It's not just another rapid test," he said. **O'Rourke confident** **Tributes flow for** **Gus clause: How NRL juvenile can bounce back from 'little mistake'** **'lovable larrikin' killed in horror crash** **plans to fix its Nine commentary problem**
It's positioned to change how frontline clinicians manage the estimated 80 million acute respiratory infection visits in the US each year by bringing more appropriate antibiotic prescribing into the point-of-care workflow.

"Reimbursement has been encouraging, with more than 90% of claims being paid, broad Medicare recognition and private payers typically reimbursing above Medicare rates.

Commercial rollout is underway after Lumos signed a six-year exclusive national US distribution agreement with PHASE Taylor and Travis spark traffic mayhem amid new wedding plot twist



"PHASE has in turn established sub-distribution relationships with Henry Schein, McKesson, NDC and others, representing more than 2,000 trained reps," Ward said.

Motoring News

message accused Aussie 'Serious': Car brands tipped to exit Aus
killer sent after Thai teen murdered
Our own and PHASE's field teams are hyper-focused on the top 100 urgent care parent entities, which alone account for roughly half of all US urgent care sites, while partners like Henry Schein and McKesson cover the long tail of smaller practices.

Commercial Real Estate

Mander marked down \$100m burger empire's over \$635k school budget blunder
This is a capital-efficient way to move the needle in volumes and influence are highest."

Large Ads in hollow

Use of FebriDx is also being established within the WellStreet Urgent Care network.
He is incredible': The blind date that led to Ariarne Titmus finding love
WellStreet is a good example of how we approach large urgent care accounts," Ward said.

News

"The fear is real': Darren Robertson on life as a top chef

Police & Courts

"We started by piloting FebriDx at a single moderately complex WellStreet site in Fayetteville, Georgia, before CLIA waiver to prove clinical value and refine workflow," Ward said.
Sick way former QRL star groomed girl, 12, for howchiptestrefusio
Aussie made \$1m in 6 months

Notional

It was to prove clinic

"After CLIA waiver, that pilot expanded to more than 40 sites and is now scaling across the broader WellStreet footprint in multiple states."

Ward said FebriDx now had the regulatory clearance, clinical evidence, economic rationale and commercial infrastructure to become a standard POC tool for managing acute respiratory infections.

Don't miss out on the headlines from Stockhead. Followed categories will be added to My News.

"The next respiratory season is about converting that foundation into visible, repeat utilisation and revenue across a growing base of high-value accounts."

Follow

Beyond FebriDx, Lumos is also involved in a range of POC development programs through commercial and technical collaborations.

Atomo grows supply partnerships and in-house tests

[Atomo Diagnostics \(ASX:AT1\)](#) powers part of the POC testing supply chain, but also develops and commercialises its own rapid diagnostic tests.

Its Pascal platform is used to make single-use test cassettes for rapid blood testing outside traditional laboratories.

The design is focused on improving ease of use, consistency and suitability for testing in clinics, pharmacies and other POC environments.

A key commercial relationship is its role as a supplier of these test cassettes to Lumos for their FebriDx test.

Atomo has an established presence in infectious disease testing, including HIV self-tests in markets such as Australia, New Zealand and the UK.

It has also developed a rapid syphilis test, targeting a sexually transmitted infection (STI) that has re-emerged as a growing public health concern in several developed markets, including Australia and the US, after years of decline.

The company also has early-stage programs in liver health testing. Atomo said recent new customers reflected growing interest in its test solutions as a scalable foundation for rapid diagnostic test development including self-testing at home.

Shift beyond POC testing to remote monitoring

While point-of-care testing continues to expand, [Adherium \(ASX:ADR\)](#) sits within a broader shift toward remote monitoring and decentralised healthcare.

Adherium's FDA-cleared Hailie Smartinhaler targets poor medication adherence in respiratory medicine, which is a key driver of avoidable flare-ups, hospitalisations and declining disease control.

Chief commercial officer John Perry told *Stockhead* the device attached to standard asthma and COPD inhalers, automatically recording when medication was taken and capturing real-world usage data between clinical visits.

"Most adherence programs fail because they depend on the patient adopting a new habit," he said.

"Ours does not because capture is passive, so the data keeps flowing even from the older, disengaged, hard-to-reach patients who need it most.

"On that foundation, care moves off patient recall and the occasional in-clinic snapshot and onto objective, real-world data captured between visits.

Perry said the data provided from the Hailie Smartinhaler was already changing clinical decisions.

"Clinicians see whether controller medication is actually being taken, whether reliever use is climbing and whether technique is the real problem," he said.

He said it then became a matter of "coach or prescribe" where care teams could tell whether the fix was a technique correction or a medication change.

And rather than adding another monitoring task for stretched clinicians, Adherium operates a managed care model where its team monitors adherence data, engages patients between appointments and escalates only clinically significant cases.

"Routine support is handled remotely, and only the patients who need clinical review reach the clinician," Perry said.

Adherium is also building a strong case for adoption, backed by clinical evidence from its iCARE program with Intermountain Health, based in Utah in the US, which has deployed 4,000 Hailie Smartinhalers across up to 2500 asthma and COPD patients in five healthcare facilities.

"Patients on Hailie-connected controllers used them as prescribed roughly two-thirds of the time, against the one-in-five typically reported in this population," Perry said.

"Nearly four in 10 cleared 80% adherence, the threshold associated with roughly half as many respiratory attacks."

The improvement translated into a 50.3% reduction in hospital admissions, a 20% reduction in emergency department visits and a 57% fall in annual cost of care per patient, from US\$36,837 to US\$15,899. Patient engagement remained high, with retention above 90% at 12 months.

Perry said moves to value-based care, where providers were paid for outcomes rather than activity, was driving a new commercial model well suited to Adherium.

"The iCARE cost-of-care reductions are exactly what health systems and payers now buy under value-based reimbursement," he said.

"So this is not a pivot away from revenue. It is the path to larger, stickier, outcomes-linked revenue, and to Adherium becoming a digital respiratory care partner rather than a connected device company."

This story does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

At Stockhead we tell it like it is. While Lumos Diagnostics is a Stockhead advertiser, the company did not sponsor this article.

Originally published as [ASX healthcare stocks riding the point-of-care testing wave](#)

Group/Corporate subscriptions	Meet the team	FAQs	The Daily Telegraph	Find Your Local
The Courier Mail app	Job opportunities	Standards of practice	The Advertiser	Foxsports
Today's Paper	Code of conduct	Letter to the Editor	news.com.au	Foxtel
Newsletters	Subscription FAQs	Licensing & Reprints	The Australian	Hipages
	Subscription terms	Advertise with us	The Mercury	Kayo
	Financial Hardship Policy		Geelong Advertiser	My Tributes
			The Cairns Post	odds.com.au
			Gold Coast Bulletin	Punters
			Townsville Bulletin	racenet.com.au
			The Chronicle	realestate.com.au
			NT News	Sky News
			The Weekly Times	Coupons
			CODE Sports	



A NOTE ABOUT RELEVANT CONTENT: We collect information about the content (including ads) you use across this site and use it to make both advertising and content more relevant to you on our network and other sites. Find out more about our policy and your choices, including how to opt-out of targeted advertising based on your browsing behaviour on our network. Sometimes our articles will try to help you find the right product at the right price. We may receive payment from third parties for publishing this content or when you make a purchase through the links on our sites.

Nationwide News Pty Ltd © 2026. All times AEST (GMT +10). Powered by WordPress.com VIP

[Privacy policy](#)
[Relevant ads opt-out](#)
[Cookie policy](#)
[Terms of use](#)